A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274
Latest Information Update: 25 Jun 2018
At a glance
- Drugs JNJ 48816274 (Primary)
- Indications Insomnia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Janssen-Cilag
- 15 Jun 2018 Status changed from recruiting to completed.
- 26 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 26 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Mar 2018.